Infectious disease modeller and leader of the Infection Epidemiology and Policy Analytics Group at the @KirbyInstitute.
Joined August 2021
- Tweets21
- Following30
- Followers60
- Likes1
Our new preprint examines factors associated with COVID-19 booster vaccine effectiveness, showing that both time since vaccination and recency of the vaccine immunogen contribute to declining VE and giving support for regular vaccine updates.
bit.ly/46Y2VBr @IAP_Sydney
9
New work from @KirbyInstitute shows viral clearance predicts clinical protection after COVID-19 treatment. Super important finding to speed up drug development to protect vulnerable populations. Great working with @ProfStephenKent @markpoliz @Tari_Turner thelancet.com/journals/lanmi…
Our latest manuscript aggregates all available data to show that updated COVID vaccines increase antibodies to a future variant by 40% compared to last season's vaccine. Another great @KirbyInstitute collaboration between @IAP_Sydney and @viralvaxlab medrxiv.org/content/10.1101/…
Deborah Cromer retweeted
Strong link between early viral load reduction by anti-COVID treatments and clinical efficacy.
Helps rapidly progress better treatments.
Bravo, great work by Khoury, Davenport and team. @IAP_Sydney @TheDohertyInst @KirbyInstitute @viralvaxlab medrxiv.org/content/10.1101/…
Great news - new evidence shows that the effectiveness of COVID-19 treatments can be determined based on how fast treated subjects can clear the virus. medrxiv.org/content/10.1101/… More great work from @IAP_Sydney at @KirbyInstitute
Get boosted! Our new research in Nature Medicine shows both normal and bivalent boosters increase antibody levels, though variant boosters give on average 60% more antibodies. #COVID19Abs nature.com/articles/s41591-0… @IAP_Sydney @KirbyInstitute @ProfStephenKent
Deborah Cromer retweeted
Neutralizing #antibody titers elicited by either ancestral or bivalent #COVID19 #vaccine boosters are predicted to increase protection against severe disease due to #SARSCoV2 variants. @DebCro @IAP_Sydney @KirbyInstitute
nature.com/articles/s41591-0…
Another win for neutralising antibodies! Who would have thought they are also correlated with protection against Severe COVID-19?? (Well maybe @IAP_Sydney would!) #COVID19Abs nature.com/articles/s41467-0… Great working with @m_steain @sarah_sasson @ProfStephenKent @KirbyInstitute
Deborah Cromer retweeted
Do you like your covid-19 vaccines to give you a good dose of neutralising antibodies? You should because we've shown they correlate not only with protection from symptomatic but also severe disease! Another great collab with @DebCro nature.com/articles/s41467-0…
Some data (to complement the range of opinions) on variant boosters in our latest preprint medrxiv.org/content/10.1101/…
Why to make of the BA.5 boosters coming soon?
The range of opinions
latimes.com/science/story/20… @LNeergaard @AP @Latimes @US_FDA
time.com/6208623/omicron-boo… @AliceParkNY @TIME @DrPaulOffit
Our latest meta-analysis comparing ancestral + variant based boosters. Shows the gain from variant boosters is very dependent on the existing protection in the population. medrxiv.org/content/10.1101/… @IAP_Sydney @KirbyInstitute @ProfStephenKent @kanta_subbarao @TheDohertyInst
Follow up on this seminar - the paper I was discussing on correlates of severe COVID-19 is now up as a preprint here medrxiv.org/content/10.1101/…
Join us online for the next CMMID seminar on "neutralising antibodies as a correlate for predicting protection from #COVID19 disease".
📆 Thursday 9 June
🕛 11:00 BST
🗣️ Dr @DebCro | @KirbyInstitute
🔗 bit.ly/3misWE6
2
Deborah Cromer retweeted
What role do T cells play in vaccine-induced immunity to SARS-CoV-2? Discussed here: go.nature.com/3y9zhIV
@sarah_sasson
@DebCro
@TricckyLab
@profstephenkent
@viralvaxlab
@EJohnWherry
#COVID-19 #vaccines #SARSCoV2
Our latest preprint shows that neutralising antibodies predict protection from severe COVID-19. Great collaborating with @ProfStephenKent @m_steain on this important work from the @KirbyInstitute medrxiv.org/content/10.1101/…
New preprint from our group combining work from multiple studies and showing a threshold for neutralising antibodies protecting from SARS-CoV-2. Great collaborating as always with @ProfStephenKent @m_steain @TricckyLab medrxiv.org/content/10.1101/…
2
Deborah Cromer retweeted
Commentary in @Nature on our analysis of dosing and timing of antibody therapies for COVID-19
Pre-print at medRxiv doi.org/10.1101/2022.03.21.2…
Deborah Cromer retweeted
Check out Dr Deborah Cromer's interview with @normanswan on today's @RadioNational Health Report discussing our analysis of antibody treatments for COVID-19
abc.net.au/radionational/pro…
@KirbyInstitute @markpoliz @AndelLestcourt @NSkoetz @Monash_SPHPM
Are monoclonals, convalescent plasma or hyperimmune Ig an effective treatment strategy for COVID-19? Check out the latest analysis. Researchers at @KirbyInstitute in collab with our @erica_m_wood @ZoeMcquilten Khai Li Chai and others show timing matters! medrxiv.org/content/10.1101/…
@EricTopol Have you seen our preprint showing that passive abs are most effective when given earlier, and could have been given at much lower doses to achieve 90% of the efficacy? (available online today)
doi.org/10.1101/2022.03.21.2…
nitter.gq/DebCro/status/15064794…
New work from our group showing passive antibodies work best when given early. Very effective as prophylaxis / in early stages - once in hospital they have little to no effect.
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
doi.org/10.1101/2022.03.21.2…
New work from our group showing passive antibodies work best when given early. Very effective as prophylaxis / in early stages - once in hospital they have little to no effect.
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
doi.org/10.1101/2022.03.21.2…
